A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A study to evaluate the safety, efficacy and bone changes with combination therapy of intravenous (IV) infused DKN-01 and lenalidomide/dexamethasone, versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma (MM) patients
Multiple Myeloma
DRUG: DKN-01 300 mg|DRUG: DKN-01 600 mg|DRUG: Standard of Care
Fluorine F18 sodium fluoride positron emission tomography (NaF-PET/CT) standard uptake value (SUV), SUV as measured by NaF-PET/CT in both myeloma bone lesions and normal bone, Pre-study to after 6 months of therapy|Fluorine F18 sodium fluoride positron emission tomography (NaF-PET/CT) influx constant (Ki), Ki as measured by NaF-PET/CT in both myeloma bone lesions and normal bone, Pre-study to after 6 months of therapy|F18 fluorodeoxyglucose positron emission tomography (FDG-PET/CT) standard uptake value (SUV), SUV as measured by FDG-PET/CT in both myeloma bone lesions and normal bone, Pre-study to after 6 months of therapy|Number of patients with treatment emergent adverse events, Baseline to study completion (approximately 7 months)
Overall response rate (ORR), Baseline to study completion (approximately 7 months)|Progression free survival (PFS), Baseline to study completion (approximately 7 months)|Duration of response, Baseline to study completion (approximately 7 months)|Overall survival, Baseline to study completion (approximately 7 months)|Pharmacokinetics: area under the concentration - time curve (AUC) of a single dose of DKN-01, Dosing interval of 2 weeks following the first dose in Cycle 1|Pharmacokinetics: maximum plasma concentration (Cmax) of a single dose of DKN-01, Dosing interval of 2 weeks following the first dose in Cycle 1|Pharmacokinetics: trough DKN-01 concentrations on Cycle 2 and Cycle 3, Cycle 2 Day 1 Pre-dose, Cycle 3 Day 1 Pre-dose
A study to evaluate the safety, efficacy and bone changes with combination therapy of intravenous (IV) infused DKN-01 and lenalidomide/dexamethasone, versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma (MM) patients